Dr. Jianhua Zhu reports

BIONEUTRA GLOBAL CORPORATION ANNOUNCES CHANGE OF DIRECTORS AND IMPLEMENTATION OF OMNIBUS SECURITY BASED COMPENSATION PLAN

Bioneutra Global Corp. has appointed Dr. Michael Z.C. Li and Michael Tse to its board of directors, effective as at June 23, 2023, subject to the approval of the TSX Venture Exchange. Dr. Li and Mr. Tse join Dr. Jianhua Zhu, C.H. William (Bill) Cheung and Robin Le Fevre on the board of directors for the ensuing year.

Dr. Li, MBA, MSc, MD, has over 30 years of experience in the medical, nutrition and natural health products sectors in Asia Pacific and North America with expertise in research and development, clinical trials, technology assessment, new product development, commercialization, business and market development, as well as strategic planning. He has worked as a general physician and held various positions and project management roles in a number of private, public and multinational companies. Dr. Li is also an adjunct professor at the University of British Columbia in food, nutrition and health who assists with the management of research activities, participates as an active committee member for graduate student research, and serves as a co-investigator with faculty members on specific projects.

Mr. Tse, as the executive vice-president, international, and board director of C-Polar Technologies Inc., a Hong Kong corporation, oversees the business development in international markets, with a focus on Hong Kong, China and Asia Pacific. He is also the chief executive officer and executive director of Green Leader Holdings Group Ltd. where he spearheaded investment opportunities in the area of agriculture-related projects in the ASEAN (Association of Southeast Asian Nations) region.

The CEO, Dr. Zhu, states: "We are fortunate to have Dr. Li and Mr. Tse appointed to the company's board of directors to assist with the continued growth and development of the company. I look forward to the insights they will bring to the board and believe their appointments will be a great asset to Bioneutra."

Furthermore, the CEO, Dr. Zhu, states: "I would like to recognize Mr. Bill Smith, for being a director and the company's chairman for many years and providing his dedicated service and involvement with the company since its early days. On behalf of the board of directors, I would like to thank Mr. Smith for his valuable contributions, commitment, dedication and assistance to the company. Mr. Smith will be missed and his input during his time on the board was instrumental in the many successes of Bioneutra. As well, thank you to Mr. Ken Lin for your contributions with your experience and insight. We wish these former directors every success in their future endeavours."

Bioneutra is also pleased to announce that shareholders have approved the company's newly adopted share-based compensation plan at the company's annual general and special meeting of shareholders held on June 23, 2023.

The omnibus plan includes a rolling stock option plan under which the number of common shares of the company that are issuable pursuant to the exercise of stock options is equal to up to a maximum of 10 per cent of the issued and outstanding common shares of the company as at the date of any stock option grant, and a fixed security-based compensation plan (other than the stock option plan) under which the number of common shares of the company that are issuable pursuant to all such security-based compensation plan (other than the stock option plan) in aggregate is a fixed specified number of common shares of the company up to a maximum of 10 per cent of the common shares of the company as at the date of implementation of the most recent of such security based compensation plan (other than the stock option plan). The omnibus plan also includes, among other things, allowing option holders to exercise options on a cashless exercise or net exercise basis.

The 10-per-cent fixed security-based compensation plan (other than stock options) allows for the issuance of stock appreciation rights, deferred share units, restricted share units, and performance share units and/or any other compensation or incentive mechanism involving the issuance or potential issuance of securities of the company from treasury.

The omnibus plan is subject to final acceptance by the TSX Venture Exchange. No awards have been granted to date under the omnibus plan.

About Bioneutra Global Corp.

Bioneutra is an award-winning, sector-leading Canadian company in the business of research and development, production, and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages with a focus on its lead product -- VitaFiber IMO.

We seek Safe Harbor.